The reversible nature of epigenetic modifications makes them excellent therapeutic targets (Cheng et al., 2019), exemplified by our study using tranylcypromine (TCP), an inhibitor of the histone H3 lysine 4 (H3K4) demethylase LSD1 (KDM1A), to demonstrate that drug-induced epigenetic remodeling could reprogram acute myeloid leukemia (AML) cells to respond to all-trans retinoic acid (ATRA, tretinoin)-based therapy (Schenk et al., 2012). This evidence concerns the gene KDM1A and acute myeloid leukemia.